Related Experiment Video
Updated: Jan 7, 2026
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
Case report of intracranial tumor with serum MOG-IgG positivity
Zhuo Min1, Lingru Wang1, Yulai Kang2
1Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Army Medical Centre of People's Liberation Army (PLA), Army Medical University, Chongqing, China.
Objective:
To deepen understanding of the correlation between intracranial tumor and serum myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) positivity, emphasizing the importance of avoiding misdiagnosis.
Methods:
We report a case involving a 24-year-old Chinese male whose clinical manifestations included slowed responsiveness, dysarthria, and right-sided limb weakness. Beyond serum MOG-IgG positivity, the nature of the central nervous system lesion was further evaluated based on therapeutic response and multimodal imaging.
Results:
The patient exhibited serum MOG-IgG positivity with an upward trend in titers. Immunotherapy failed to provide sustained and effective control of disease progression. Integrating the therapeutic response and characteristic imaging changes, a final diagnosis of malignant intracranial tumor was reached. Following diagnosis, he declined further oncologic therapy and died one month later due to a pulmonary infection.
Conclusion:
Serum MOG-IgG positivity and an initial response to immunotherapy may be misleading and contribute to diagnostic confusion with inflammatory demyelinating disorders. In atypical or treatment-refractory MOG antibody-associated disease, clinicians should remain vigilant for the possibility of a central nervous system space-occupying lesion.
